Portfolio at a glance
Securities as at September 30, 2023
|
Company |
|
Number of securities |
|
Change since 31.12.2022 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Argenx SE |
|
859 775 |
|
(32 728) |
|
USD |
|
491.63 |
|
386.9 |
|
15.4% |
|
17.5% |
|
1.5% |
|
Ionis Pharmaceuticals |
|
9 100 000 |
|
(535 000) |
|
USD |
|
45.36 |
|
377.8 |
|
15.0% |
|
17.1% |
|
6.3% |
|
Neurocrine Biosciences |
|
2 554 350 |
|
(175 650) |
|
USD |
|
112.50 |
|
263.0 |
|
10.4% |
|
11.9% |
|
2.6% |
|
Vertex Pharmaceuticals |
|
812 850 |
|
(117 673) |
|
USD |
|
347.74 |
|
258.7 |
|
10.3% |
|
11.7% |
|
0.3% |
|
Intra-Cellular Therapies |
|
3 130 950 |
|
(160 529) |
|
USD |
|
52.09 |
|
149.3 |
|
5.9% |
|
6.7% |
|
3.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alnylam Pharmaceuticals |
|
869 700 |
|
(20 300) |
|
USD |
|
177.10 |
|
141.0 |
|
5.6% |
|
6.4% |
|
0.7% |
|
Moderna |
|
1 466 075 |
|
(35 876) |
|
USD |
|
103.29 |
|
138.6 |
|
5.5% |
|
6.3% |
|
0.4% |
|
Incyte |
|
2 485 050 |
|
(406 027) |
|
USD |
|
57.77 |
|
131.4 |
|
5.2% |
|
5.9% |
|
1.1% |
|
Revolution Medicines |
|
4 646 700 |
|
(130 862) |
|
USD |
|
27.68 |
|
117.7 |
|
4.7% |
|
5.3% |
|
4.2% |
|
Agios Pharmaceuticals |
|
4 000 000 |
|
(30 792) |
|
USD |
|
24.75 |
|
90.6 |
|
3.6% |
|
4.1% |
|
7.2% |
|
Sage Therapeutics |
|
3 505 000 |
|
554 722 |
|
USD |
|
20.58 |
|
66.0 |
|
2.6% |
|
3.0% |
|
5.9% |
|
Celldex Therapeutics |
|
1 900 000 |
|
100 000 |
|
USD |
|
27.52 |
|
47.9 |
|
1.9% |
|
2.2% |
|
4.0% |
|
Exelixis |
|
2 369 725 |
|
(284 775) |
|
USD |
|
21.85 |
|
47.4 |
|
1.9% |
|
2.1% |
|
0.7% |
|
Macrogenics |
|
9 779 963 |
|
850 000 |
|
USD |
|
4.66 |
|
41.7 |
|
1.7% |
|
1.9% |
|
15.8% |
|
Arvinas |
|
2 120 000 |
|
(16 412) |
|
USD |
|
19.64 |
|
38.1 |
|
1.5% |
|
1.7% |
|
4.0% |
|
Relay Therapeutics |
|
4 875 000 |
|
754 280 |
|
USD |
|
8.41 |
|
37.5 |
|
1.5% |
|
1.7% |
|
4.0% |
|
Crispr Therapeutics |
|
880 000 |
|
(8 605) |
|
USD |
|
45.39 |
|
36.6 |
|
1.5% |
|
1.7% |
|
1.1% |
|
Wave Life Sciences |
|
4 494 458 |
|
– |
|
USD |
|
5.75 |
|
23.7 |
|
0.9% |
|
1.1% |
|
4.5% |
|
Essa Pharma |
|
7 879 583 |
|
– |
|
USD |
|
3.09 |
|
22.3 |
|
0.9% |
|
1.0% |
|
17.9% |
|
Black Diamond Therapeutics |
|
8 117 839 |
|
2 740 000 |
|
USD |
|
2.87 |
|
21.3 |
|
0.8% |
|
1.0% |
|
15.7% |
|
Rivus Pharmaceuticals 1) |
|
|
|
|
|
USD |
|
|
|
16.0 |
|
0.6% |
|
0.7% |
|
|
|
Beam Therapeutics |
|
693 121 |
|
– |
|
USD |
|
24.05 |
|
15.3 |
|
0.6% |
|
0.7% |
|
0.9% |
|
Scholar Rock Holding |
|
2 132 725 |
|
– |
|
USD |
|
7.10 |
|
13.9 |
|
0.6% |
|
0.6% |
|
3.8% |
|
Generation Bio Co. |
|
3 608 280 |
|
– |
|
USD |
|
3.79 |
|
12.5 |
|
0.5% |
|
0.6% |
|
5.5% |
|
Fate Therapeutics |
|
4 839 779 |
|
– |
|
USD |
|
2.12 |
|
9.4 |
|
0.4% |
|
0.4% |
|
4.9% |
|
Mersana Therapeutics |
|
5 205 925 |
|
1 139 725 |
|
USD |
|
1.27 |
|
6.1 |
|
0.2% |
|
0.3% |
|
4.3% |
|
Molecular Templates 2) |
|
1 029 820 |
|
283 686 |
|
USD |
|
6.32 |
|
6.0 |
|
0.2% |
|
0.3% |
|
19.2% |
|
Esperion Therapeutics |
|
4 194 064 |
|
– |
|
USD |
|
0.98 |
|
3.8 |
|
0.2% |
|
0.2% |
|
3.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Radius Health – Contingent Value Right |
|
8 733 538 |
|
– |
|
USD |
|
0.00 |
|
0.0 |
|
0.0% |
|
0.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
2 520.3 |
|
100.0% |
|
113.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
0.4 |
|
|
|
0.0% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(306.6) |
|
|
|
(13.8%) |
|
|
|
Net Asset Value |
|
|
|
|
|
|
|
|
|
2 214.1 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1) Unlisted company
2) Share split 1:15 as at August 14, 2023
Exchange rate as at 30.09.2023: USD/CHF: 0.9153